What is Humatrope?
Humatrope® (somatropin [rDNA origin] for injection) is a treatment made by Eli Lilly and Company.
Humatrope is a Bio-Identical form of Human Growth Hormone (HGH), produced using recombinant DNA technology.
Bio-identical means that Humatrope is molecularly identical to that which is produced by the human body -- it just comes from a laboratory rather than from the Pituitary Gland.
What is Humatrope used for?
Humatrope is used for the treatment of conditions that are associated with pediatric and adult Human Growth Hormone deficiency.
For pediatric patients, Humatrope is used for the long-term treatment of patients who have stunted growth due to an inadequate secretion of normal endogenous Growth Hormone.
Humatrope is used for the treatment of short stature associated with Turner Syndrome (TS) in patients whose epiphyses are not closed (the rounded end of a long bone).
Humatrope helps children that are exhibiting a slower than normal growth rate due to Human Growth Hormone deficiency reach their normal final adult height.
Humatrope can only be used for this purpose until the epiphyseal plates have closed, because, after these structures have closed, height is essentially "locked in," and the patient can no longer grow taller.
Beyond this point, providing HGH levels associated with childhood will lead to symptoms of Acromegaly, in which the bones become thicker and wider without becoming longer.
Humatrope is used for the extended treatment of Idiopathic Short Stature (ISS), defined by a height that is more than two standard deviations below the corresponding average height for the individual's age, etc., as well as for individual's whose growth rates are unlikely to achieve a height within the normal range of the adult averages.
The patients should demonstrate unclosed epiphyses and for whom evaluation excludes other possible causes associated with short height stature that could and should be treated by other means.
Humatrope Therapy for Adults
For adult patients, Humatrope is used for replacement of endogenous Growth Hormone in adults with Growth Hormone deficiency. Adult Human Growth Hormone Deficiency comes in two forms:
1. Adult Onset: Patients who have Growth Hormone deficiency as a result of pituitary disease, radiation therapy, hypothalamic disease, surgery, or trauma.
Adult-onset HGH deficiency can also be the result of age-related natural HGH decline, in which the body slowly loses its ability to produce sufficient HGH to meet the needs of the body, typically after the age of thirty.
2. Childhood Onset: Patients who were HGH deficient beginning in childhood who have had Growth Hormone deficiency confirmed as an adult before replacement therapy with Humatrope, or any other Growth Hormone brand, is started.
Although Humatrope only encourages growth until the end of puberty, the patient still needs Human Growth Hormone to sustain normal cellular metabolism and can benefit from a reduced dosage of Humatrope.
Humatrope Dosages for Pediatric Patients
The Humatrope dosage and administration schedule should be individualized for each patient. Therapy should not be continued if epiphyseal fusion has occurred.
Response to Growth Hormone therapy tends to decrease with time. However, failure to increase growth rate, particularly during the first year of therapy, should prompt close assessment of compliance and evaluation of other causes of growth failure such as hypothyroidism, under-nutrition and advanced bone age.
For Growth Hormone-deficient pediatric patients, the recommended weekly dosage is 0.18 mg/kg (0.54 IU/kg) of body weight.
The maximal replacement weekly dosage is 0.3 mg/kg (0.90 IU/kg) of body weight. It should be divided into equal doses given either on three alternate days, six times per week or daily. The intravenous route of administration is the preferred method.
For Turner Syndrome patients, a weekly dosage of up to 0.375 mg/kg (1.125 IU/kg) of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given either daily or on three alternate days.
For patients with Idiopathic Short Stature, a weekly dosage of up to 0.37 mg/kg of body weight administered by subcutaneous injection is recommended. It should be divided into equal doses given six to seven times per week.
Humatrope Dosages for Adult Patients
For Growth Hormone-deficient adult patients, the recommended dosage at the start of therapy is no more than 0.006 mg/kg/day (0.018 IU/kg/day) given as a daily subcutaneous injection. The dose may be increased according to individual patient requirements to a maximum of 0.0125 mg/kg/day (0.0375 IU/kg/day).
About Eli Lily and Company
Founded in 1876 by Colonel Eli Lilly, Eli Lilly and Company is a globe-spanning research and pharmaceutical firm with it's headquarters in Indianapolis, Indiana.
The firm achieved more than $24 billion in revenue in 2011 and spends $5 billion dollars a year in research alone. The company has 38,000 employees and manufacturing plants in 13 countries.
How do I get a Prescription for Humatrope?
To get started with your own co-created HGH, Testosterone, Sermorelin or HCG therapy program, please fill out the contact form on the right hand side of our site and then give us a call at 1-800-688-9673.
We specialize in providing quality hormone therapy and replacement programs to patients over the age of thirty that suffer from hormone imbalance or struggle with weight-related issues.
Simply give us a call to learn more about how we can help you as a patient overcome hormone imbalance and improve your health and well-being.
Quality care from medical professionals is just a phone call away and we have qualified professionals prepared to field any questions that you may have!
List of USA state clinics - click a flag below for blood testing clinics.
Word Count: 903